Healthcare Industry News:  Telik 

Biopharmaceuticals Oncology

 News Release - September 25, 2006

Telik Updates ASSIST-1 Status

PALO ALTO, Calif., Sept. 25 (HSMN NewsFeed) -- Telik, Inc. (Nasdaq: TELK ) announced today that the pre-specified number of events have been reached on the ASSIST-1 Phase 3 trial in platinum refractory or resistant ovarian cancer.

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTAź, a tumor-activated small molecule product candidate. TELCYTA is in four Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second development candidate, TELINTRA(TM), is in clinical development in myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.Telik.com.

Source: Telik

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.